Mcp

Metoclopramide Hydrochloride, the active ingredient in Mcp, is a dopamine antagonist / antiemetic presented as an oral dosage form for oral use. It treats nausea and vomiting, gastroparesis, functional dyspepsia, and helps prevent chemotherapy‑induced nausea in adult patients.

GNH USA supplies Mcp as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metoclopramide Hydrochloride is indicated for conditions affecting the gastrointestinal tract and the chemoreceptor trigger zone.

- Nausea and vomiting: reduces frequency and severity of episodes. - Gastroparesis: enhances gastric emptying and relieves related symptoms. - Functional dyspepsia: alleviates upper abdominal discomfort and early satiety. - Prevention of chemotherapy‑induced nausea: lowers incidence of acute and delayed nausea.

Metoclopramide Hydrochloride may cause a range of adverse reactions.

Common Side Effects: - Drowsiness - Fatigue - Restlessness or akathisia - Diarrhea - Dry mouth - Headache

Serious or Rare Side Effects: - Extrapyramidal symptoms, including dystonia - Tardive dyskinesia with long‑term use - Neuroleptic malignant syndrome - Severe depression or suicidal thoughts - Seizures - Anaphylactic reactions

Before prescribing Metoclopramide Hydrochloride, clinicians should consider several safety factors.

- Pregnancy: use only if potential benefit justifies the risk to the fetus. - Elderly patients: monitor closely for central nervous system effects such as confusion or falls. - Renal impairment: dose adjustment may be required due to reduced clearance. - History of movement disorders: avoid use because of increased risk of extrapyramidal reactions. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Metoclopramide Hydrochloride can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Anticholinergic agents: may diminish the pro‑kinetic effect. - CYP2D6 inhibitors (e.g., quinidine, fluoxetine): can raise metoclopramide plasma concentrations. - MAO inhibitors: increase risk of hypertensive crisis.

Moderate Interactions (Monitor Closely): - Opioids: additive central nervous system depression. - Antidepressants (SSRIs, SNRIs, tricyclics): heightened risk of serotonin syndrome. - Alcohol: may enhance drowsiness and dizziness.